Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials

MeSH terms

• Antineoplastic Agents / therapeutic use
• Benzamides
• Blast Crisis / drug therapy
• Blast Crisis / pathology
• Clinical Trials, Phase II as Topic
• Disease-Free Survival
• Follow-Up Studies
• Humans
• Imatinib Mesylate
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
• Leukemia, Myeloid, Accelerated Phase / drug therapy
• Leukemia, Myeloid, Accelerated Phase / pathology
• Piperazines / therapeutic use*
• Pyrimidines / therapeutic use*
• Treatment Outcome